Powles T, et al. A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). ASCO-GU 2019, abstract 545.
Podcast: Progress in PARP inhibitors - An exciting option for treating metastatic prostate cancer?
dec 2023 | Uro-oncologie